首页> 美国卫生研究院文献>Clinical and Experimental Immunology >Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status
【2h】

Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status

机译:碳酸酐酶II抗体存在于原发性胆汁性肝硬化(PBC)中与抗线粒体抗体状态无关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antibody to carbonic anhydrase II, an enzyme abundantly present in biliary epithelium, has been proposed as a diagnostic marker for antimitochondrial antibody-negative PBC. In this study we determine its prevalence and clinical significance in a large series of patients with antimitochondrial antibody-positive and -negative PBC. Reactivity to carbonic anhydrase II was sought by Western immunoblotting in sera from 215 consecutive patients with PBC (26 antimitochondrial antibody-negative), 13 with autoimmune hepatitis, 25 with primary Sjögren's syndrome (pSS), 12 with systemic sclerosis, 19 with systemic lupus erythematosus and 73 healthy subjects. The prevalence of antibody to carbonic anhydrase II (titre 1:100) in PBC was 8%. No specific reactivity to carbonic anhydrase II was found in antimitochondrial antibody-negative PBC (7% versus 8% in antimitochondrial antibody-positive PBC). Ascites (P = 0.006) and Sjögren's syndrome (SS) (P = 0.022) in PBC were significantly associated with presence of the antibody. In patients with SS associated with PBC, the prevalence (19%) was similar to that observed in pSS (16%). At a serum dilution of 1:40, the prevalence of positive sera in PBC rose to 27% but disease specificity was reduced. Our findings in a large population of PBC patients rule out a relation between presence of antibody to carbonic anhydrase II and lack of antimitochondrial antibody. The higher prevalence of ascites found in positive patients warrants further evaluation.
机译:碳酸酐酶II(胆汁上皮中大量存在的一种酶)的抗体已被提议作为抗线粒体抗体阴性PBC的诊断标记。在这项研究中,我们确定了其在抗线粒体抗体阳性和阴性PBC的大量患者中的普遍性和临床意义。通过Western免疫印迹对连续215例PBC患者(26例抗线粒体抗体阴性),13例自身免疫性肝炎,25例原发性干燥综合征(pSS),12例系统性硬化症,19例系统性红斑狼疮患者的血清中的碳酸酐酶II进行反应73名健康受试者。 PBC中抗碳酸酐酶II(滴度1:100)的抗体的发生率为8%。在抗线粒体抗体阴性的PBC中未发现对碳酸酐酶II的特异性反应(抗线粒体抗体阳性的PBC中为7%,而对8%)。 PBC中的腹水(P = 0.006)和干燥综合征(SS)(P = 0.022)与抗体的存在显着相关。在伴有PBC的SS患者中,患病率(19%)与在pSS中观察到的患病率(16%)相似。在1:40的血清稀释度下,PBC中阳性血清的患病率上升至27%,但疾病特异性降低。我们在大量PBC患者中的发现排除了碳酸酐酶II抗体的存在与抗线粒体抗体的缺乏之间的关系。在阳性患者中发现的腹水患病率较高,值得进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号